“Protect” ML29346 (Dr. Feiner’s IST)

Status: Not Enrolling

ClinicalTrials.gov Identifier: NCT02302989

Pro-Con: Prospective double-blind randomized study to evaluate Lucentis for prophylaxis against the conversion to neovascular age-related macular degeneration (AMD in high-risk eyes)

Condition: AMD in Fellow Eye

Study Type: Interventional

Duration: 24 months

Eligibility:

  • Ages: Child, Adult, Senior
  • Sexes: All
  • Accepts Healthy Volunteers: No

For additional information, please click here

Go Back
This entry was posted in Uncategorized. Bookmark the permalink.